Amgen Inc. (AMGN) Stock Analysis
Is AMGN a good investment?
Amgen Inc. (AMGN) has a Plutrex AI rating of 33.0/100 as of October 01, 2026, indicating a Sell consensus. The stock is not classified as halal-compliant. Key strength: World-class FCF of $10.18B annually (operating margin 35.55% vs. industry 30.82%, +15.3% premium) funds dividend, debt service, and potential deleveraging simultaneously — a genuine cash generation moat. Main concern: PEG ratio of 4.58 (WORSENED from 4.45 last week as stock rose +3.8% to $421.51 while 5-year EPS CAGR held at 5.72% and analyst consensus barely moved to $401.94) — paying 4.58x growth rate for a company growing EPS at sub-6% is extreme overvaluation; DCF implies 27-41% downside to $265-$320 fair value range.
Investment Summary
AMGN at $421.51 remains deeply overvalued relative to its fundamental drivers. The stock now trades at a PEG of 4.58 (up from 4.45 last week) — paying 4.58x the 5-year EPS growth rate of 5.72%, which is the single most damning valuation metric. P/E of 26.18x is justified only if growth were 13%+; instead it sits at sub-6%. Analyst consensus target is $401.94, implying -4.6% downside from current price — the stock is already ABOVE fair value on sell-side models. The balance sheet carries $13.99B cash against extreme D/E of 4.44x (vs. industry 0.84x), a legacy of the Horizon Therapeutics acquisition. FCF of $10.18B is genuinely world-class and supports the dividend. Positive news this week: Dazodalibep succeeded in a Phase 3 Sjogren's trial ('Amgen's autoimmune drug succeeds in late-stage trial'), and dividend sustainability analysis is favorable ('Bet on These 5 Dividend Growth Stocks'). However, 'Why Amgen's 6% Dividend Raise Masks a Tougher Road Ahead' captures the core thesis — the headline positives mask an underlying structural growth problem. The Sjogren's catalyst, while real, requires a second confirmatory trial before NDA/BLA submission, pushing commercial revenue to 2027+ at earliest, which does not bridge the current 27-41% gap to DCF intrinsic value ($265-$320 range).
Key Strengths
- World-class FCF of $10.18B annually (operating margin 35.55% vs. industry 30.82%, +15.3% premium) funds dividend, debt service, and potential deleveraging simultaneously — a genuine cash generation moat
- Dazodalibep Phase 3 Sjogren's success ('Amgen's autoimmune drug succeeds in late-stage trial') adds real pipeline optionality in an underserved autoimmune market with limited approved treatments; Jefferies raised PT to $410 on the news
- Relative valuation: P/E 26.18x at -8.3% discount to industry average 28.55x, PEG 4.58 at -59.6% discount to industry average 11.33 — on a peer-relative basis, AMGN is not the most expensive biopharma, and dividend yield provides income floor for defensive allocators
Key Concerns
- PEG ratio of 4.58 (WORSENED from 4.45 last week as stock rose +3.8% to $421.51 while 5-year EPS CAGR held at 5.72% and analyst consensus barely moved to $401.94) — paying 4.58x growth rate for a company growing EPS at sub-6% is extreme overvaluation; DCF implies 27-41% downside to $265-$320 fair value range
- Extreme leverage (D/E 4.44x vs. industry 0.84x, +430% above peers) combined with slowest forward EPS growth in the peer group (5.95% next year vs. industry 136.17%) creates the worst risk-adjusted profile in the sector — most leveraged AND slowest growing simultaneously, with no near-term catalyst (Sjogren's commercial revenue 2027+ at earliest) to resolve either constraint
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
Profitability is elite: gross margin 72.7% (vs. industry 71.3%), operating margin 35.55% (vs. industry 30.82%, +15.3% premium), net margin 22.89% (vs. industry 17.03%, +34.4% premium), ROE 91.5% (vs. industry 25.64%, leverage-amplified). FCF $10.18B annually. These are genuinely best-in-class metrics. Financial health is the critical flaw: D/E of 4.44x vs. industry 0.84x — AMGN carries 5.3x more leverage than the average peer. Interest expense consumes 12.6 percentage points of margin (operating 35.55% vs. net 22.89%). Growth is structurally weak: revenue growth 9.5% (vs. industry 17.02%, -44% lag), forward EPS growth next year 5.95% (vs. industry 136.17%, a staggering -95.6% lag), 5-year EPS CAGR 5.72% (vs. industry 13.93%, -59% lag). Valuation: P/E 26.18x for 5.72% EPS growth yields PEG 4.58 — a stock priced for double-digit growth that will not materialize. DCF using $10.18B FCF, 5.72% growth, 9% discount rate implies fair value ~$240-$320. Analyst consensus $401.94 is itself 4.6% below current price.
News Sentiment
Amgen's stock has been riding a wave of optimism lately, but savvy investors are asking whether the enthusiasm is fully warranted. The biotech giant scored a major win when its experimental drug dazodalibep met its primary endpoint in a Phase 3 clinical trial for Sjogren's disease — a chronic autoimmune condition that leaves millions of patients with limited treatment options. Headlines like 'Amgen's autoimmune drug succeeds in late-stage trial' and '2 Healthcare Stocks That Just Delivered Great News for Investors' captured the market's excitement, sending shares charging ahead. The company also made waves in income-investing circles, appearing in analyses of dividend growth stocks amid rising Treasury yields — a sign that analysts view Amgen's cash generation as durable enough to sustain payouts even in a challenging rate environment. But not all coverage was rosy. The headline 'Why Amgen's 6% Dividend Raise Masks a Tougher Road Ahead' cut to the heart of Amgen's dilemma: beneath the dividend growth and pipeline wins lies a company growing earnings at just 5-6% annually while carrying debt more than five times the industry average. Investors and analysts will now watch closely for a second confirmatory Sjogren's trial — the key hurdle before Amgen can file for FDA approval, likely pushing any commercial revenue from this drug to 2027 or beyond. The question for investors: is today's stock price of $421 — already above the average analyst target of $402 — priced for the good news already?
Risk Assessment
PRIMARY RISK: Mean reversion from PEG 4.58 to a more appropriate 2.5-3.0x (given franchise quality) implies a price of $200-$272 on pure growth-adjusted metrics, or $265-$320 using DCF. Catalysts for downside: (1) Biosimilar erosion on Enbrel/other mature products accelerates, pressuring the 5.72% EPS CAGR lower; (2) Rising interest rates increase the cost of carrying $4.44x leveraged balance sheet; (3) Dazodalibep second trial fails, removing the primary pipeline narrative. UPSIDE RISKS that could delay the correction: (1) Dazodalibep second trial succeeds rapidly, accelerating commercial timeline; (2) Management announces accelerated deleveraging plan; (3) Market continues rewarding defensive dividend payers in risk-off environment. MITIGATION: Entry zone $278-$295 provides 39%+ upside to analyst consensus $401.94 and 5.1x risk/reward ratio. At current $421.51, the stock offers -4.6% to analyst consensus and -27% to -37% to DCF fair value — no margin of safety.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is AMGN a halal stock?
No, Amgen Inc. (AMGN) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for AMGN?
Amgen Inc. (AMGN) has a Plutrex AI rating of 33.0/100 with a Sell consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is AMGN a good investment?
According to Plutrex AI, AMGN has a Sell rating (33.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in AMGN?
US stocks like AMGN can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in AMGN?
Plutrex AI identifies the main risks for AMGN by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.